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IMPORTANCE Anemia affects most pregnant African women and is predominantly due to iron
deficiency, but antenatal iron supplementation has uncertain health benefits and can increase
themalaria burden.
OBJECTIVE Tomeasure the effect of antenatal iron supplementation onmaternal
Plasmodium infection risk, maternal iron status, and neonatal outcomes.
DESIGN, SETTING, AND PARTICIPANTS Randomized placebo-controlled trial conducted
October 2011 through April 2013 in a malaria endemic area among 470 rural Kenyan women
aged 15 to 45 years with singleton pregnancies, gestational age of 13 to 23 weeks, and
hemoglobin concentration of 9 g/dL or greater. All women received 5.7 mg iron/day through
flour fortification during intervention, and usual intermittent preventive treatment against
malaria was given.
INTERVENTIONS Supervised daily supplementationwith 60mgof elemental iron (as ferrous
fumarate, n = 237women) or placebo (n = 233) from randomization until 1month postpartum.
MAIN OUTCOMES ANDMEASURES Primary outcomewasmaternal Plasmodium infection at
birth. Predefined secondary outcomes were birth weight and gestational age at delivery,
intrauterine growth, andmaternal and infant iron status at 1 month after birth.
RESULTS Among the 470 participating women, 40women (22 iron, 18 placebo) were lost to
follow-up or excluded at birth; 12 mothers were lost to follow-up postpartum (5 iron, 7
placebo). At baseline, 190 of 318 women (59.7%) were iron-deficient. In intention-to-treat
analysis, comparison of womenwho received iron vs placebo, respectively, yielded the
following results at birth: Plasmodium infection risk: 50.9% vs 52.1% (crude difference, −1.2%,
95% CI, −11.8% to 9.5%; P = .83); birth weight: 3202 g vs 3053 g (crude difference, 150 g,
95% CI, 56 to 244; P = .002); birth-weight-for-gestational-age z score: 0.52 vs 0.31 (crude
difference, 0.21, 95% CI, −0.11 to 0.52; P = .20); and at 1 month after birth: maternal
hemoglobin concentration: 12.89 g/dL vs 11.99 g/dL (crude difference, 0.90 g/dL, 95% CI,
0.61 to 1.19; P < .001); geometric meanmaternal plasma ferritin concentration: 32.1 μg/L vs
14.4 μg/L (crude difference, 123.4%, 95% CI, 85.5% to 169.1%; P < .001); geometric mean
neonatal plasma ferritin concentration: 163.0 μg/L vs 138.7 μg/L (crude difference, 17.5%,
95% CI, 2.4% to 34.8%; P = .02). Serious adverse events were reported for 9 and 12 women
who received iron and placebo, respectively. There was no evidence that intervention effects
on Plasmodium infection risk were modified by intermittent preventive treatment use.
CONCLUSIONS AND RELEVANCE Among rural Kenyanwomenwith singleton pregnancies,
administration of daily iron supplementation, compared with administration of placebo,
resulted in no significant differences in overall maternal Plasmodium infection risk. Iron
supplementation led to increased birth weight.
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A nemia in pregnancy is a moderate or severe healthproblem in more than 80% of countries worldwide,but particularly in Africa, where it affects 57% of
pregnant women.1 Iron deficiency is the most common
cause and may be even more widespread, but global or
regional estimates are lacking.
Although universal antenatal iron supplementation has
been recommended since 1959,2 delivery and adherence
have been notably poor in low- and middle-income
countries.3,4 It is well established that antenatal iron supple-
mentation leads to increased maternal hemoglobin concen-
trations and a reduced risk of anemia at term,5 but the func-
tional significance of this hematologic response is uncertain.6
Iron deficiency in pregnancy has been associated with severe
anemia and maternal death, but causal evidence from ran-
domized trials is inconclusive.5 A meta-analysis of random-
ized trials of iron supplementation during pregnancy found
no evidence of benefits for maternal and neonatal health
outcomes.5
Added to these uncertainties, a trial among children7
reinforced earlier concerns that iron supplementation can
increase rates of infectious diseases, including malaria.8
Antenatal supplementation nonetheless continues to be
recommended,9 despite reports that iron deficiency is asso-
ciated with protection against Plasmodium infection in pla-
cental blood.10 In a previous randomized trial, antenatal
iron supplementation did not increase susceptibility to
Plasmodium infection,11 but its design had limitations in
allocation concealment, blinding, and data completeness.5
In highly endemic areas, P falciparum infections in preg-
nancy are usually asymptomatic, but they increase the risk
of adverse birth outcomes (reduced birth weight, intrauter-
ine growth retardation, preterm delivery, increased neona-
tal mortality) and adverse maternal outcomes (severe ane-
mia and death).12
We aimed tomeasure the effect of daily iron supplemen-
tation during pregnancy on maternal Plasmodium infection
risk. We conducted preplanned analysis of effect modifica-
tion by baseline iron status, gravidity, age, andHIV infection.
We also assessed effects of iron supplementation on gesta-
tional age at delivery, newborn size, andmaternal andneona-
tal iron status at 1 month postpartum.
Methods
The study was a double-blind, randomized trial comparing
daily supplementation with iron vs placebo, with 2 parallel
groups of pregnant women receiving daily supplementation
with andwithout iron. (Additional details are provided in the
trial protocol in Supplement 1, the statistical analysis plan in
Supplement 2, and the eMethods in Supplement 3.) The study
received ethical clearance in Kenya (Kenyatta National
Hospital/University of Nairobi) and England (London School
ofHygiene andTropicalMedicine). Allwomen in the trial pro-
vided written informed consent.
The study was conducted (October 2011–April 2013) in
Nyanza Province, Kenya, where malaria is highly endemic
and transmission is perennial. As per national and interna-
tional guidelines,13-15 pregnant women should receive daily
iron supplementation and intermittent preventive treat-
ment (IPT) for malaria with sulfadoxine-pyrimethamine. In
2008 to 2009, 31% of women in Nyanza Province reported
not having taken any iron supplements during their last
pregnancy, while 54% took them for less than 60 days.16
Sample
Localwomenaged 15 to45 yearswhoweremarried or cohabi-
tatingwere included inacommunity surveillanceprogramand
invited for pregnancy screening when having missed their
menstrual period for 10 weeks. Those whowere not in stable
relationshipswere invitedforpregnancytestingevery12weeks.
At screening,we collected stool, andwe administered a urine
pregnancy test, amedical examination including obstetric ul-
trasonography, and preventive antihelminth chemotherapy
with praziquantel and albendazole (Figure 1).
At 14 to 21 days after the initial visit but before random-
ization, we collected venous blood and measured hemoglo-
bin concentration (HemoCue301) and zinc protoporphyrin
(ZPP; Aviv206d). Erythrocytes and plasmawere stored in liq-
uid nitrogen and dry ice until analysis.
Recruitment continueduntil the target numberofwomen
was reached.We calculated thatwewouldneed 225pregnant
womenper interventiongroup (450women total) to give92%
probability of excludingno effect, assuming aPlasmodium in-
fection risk of 50% in the placebo group, a relative risk in-
crease due to iron of 35%, 5% drop-out of the iron group, and
no “drop-in” of women crossing over from the placebo group
to the iron group. To enroll this number ofwomen,we antici-
pated an 18-month recruitment period.
Women were included when they were aged 15 to 45
years, written informed consent had been obtained, they
were likely to be available for study until 1 month postpar-
tum, and they were planning to deliver in the predesignated
health facility. Women were excluded if they had obvious
intellectual disabilities or a metabolic disorder (eg, diabe-
tes); they had a medical history of sickle cell anemia or epi-
lepsy or an obstetric history suggestive of eclampsia or pre-
eclampsia; they were carrying multiples; gestational age at
the second visit was less than 13 weeks or more than 23
weeks; no venous blood was collected; or hemoglobin con-
centration was less than 9 g/dL (which has previously been
associated with adverse events such as prematurity, low
birth weight, and fetal death).17,18
Randomization and Blinding
Supplementswere given as capsules thatwere identical in ap-
pearance except for shell color. The code linking each color to
supplement typewaskept in sealedenvelopes.Oneofus (H.V.)
not involved in the field work used tables with randomnum-
bers to produce sequentially numbered, sealed, opaque en-
velopes containing the code,using simple randomizationwith
a 1:1 allocation ratio. Eligible women were allocated in order
of enrollment to the color indicated in the next available en-
velope. Participants and field staff were blinded to interven-
tion until data analysis.
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Interventions
Supplements contained iron (60 mg of elemental iron as fer-
rous fumarate, which has similar iron bioavailability as fer-
rous sulfate) or placebo; they contained no othermicronutri-
ents. Researchassistants administered supplements anddaily
observed that women swallowed their supplements.
Figure 1. Participant Flow in Trial of Iron Supplementation During Pregnancy
1130 Pregnant, took preventive
praziquantel/albendazole,
and started run-in
1804 Screened
660 Excluded
210 Head of household declined consent
427 Did not show for randomization visit
23 Hemoglobin <9 g/dL at randomization visit
674 Excluded
286 Unwilling to adhere to intervention
227 Not pregnant
137 Gestational age >23 wk
16 Medical reasons
8 Multiples pregnancy
211 Excluded (did not attend screening)
470 Randomized
2015 Invited for pregnancy screening
2957 to 3695 Rolling cohort of resident
women aged 15-45 y and
identified in census a
Lost to follow-up 1 mo after birth
5 Mothers
1 Moved away
4 Unknown reasons
13 Infants
2 Late fetal death c
5 Neonatal death
1 Moved away
3 Refused blood collection
2 Refused follow-up
Lost to follow-up 1 mo after birth
7 Mothers
2 Death
2 Refused follow-up
1 Moved away
2 No follow-up after neonatal death
9 Infants
1 Late fetal death c
4 Neonatal death
1 Refused follow-up
1 Death after 28 d of life
2 Refused blood collection
1 Twin pregnancy
21 Lost to follow-up
11 Left study area
2 Refused follow-up
8 Plasmodium infection not
determined at birth due to
fetal death (n = 1) or home
delivery (n = 7)
0 Consumed ≤90% of scheduled
supplements
1 Twin pregnancy
15 Lost to follow-up
9 Left study area
2 Refused follow-up
4 Plasmodium infection not
determined at birth due to
fetal death (n = 2) or home
delivery (n = 2)
2 Consumed ≤90% of scheduled
supplements
210 Mothers completed trial
through 1 mo postpartum
202 Infants completed trial
through 1 mo postpartum
208 Mothers completed trial
through 1 mo postpartum
206 Infants completed trial
through 1 mo postpartum
215 Completed trial through delivery 215 Completed trial through delivery
237 Included in ITT analysis
215 Included in per-protocol analysis b
233 Included in ITT analysis
215 Included in per-protocol analysis b
237 Randomized to receive iron 233 Randomized to receive placebo
a During the study, women entered
the cohort as they immigrated into
the study area or attained the
minimum eligible age (15 years) and
left the cohort as they emigrated or
attained themaximum eligible age
(45 years).
b Sample sizes <215 are due tomissing
data, which varied by outcome. In
the intention-to-treat (ITT) analysis,
missing values were replaced by
multiple imputation.
c Maternal samples were collected at
delivery so that primary outcome
could be established.
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From screening until end of intervention, local mill op-
erators added fortificant iron (target dose: 20mg/kg flour) to
grain routinely brought formilling byhomesteadmembers of
participatingwomen.Basedonweighed intake studies,wees-
timate that fortification suppliedonaverage5.7mgof elemen-
tal iron asNaFeEDTA (ferric sodiumethylenediaminetetraac-
etate) daily in pregnant women.
Follow-up
Womenwere referred to regularhealth services for routinean-
tenatal andmedical careduring intervention, including IPT for
malaria and (as required) antiretroviral therapy, but theywere
instructed not to takemicronutrient supplements other than
those supplied by our field staff. They were asked to ensure
that all diagnoses, treatments, and drugs administered were
recorded inantenatalhealthbookletsandtoalert the field team
as soon as theywent into labor. An obstetric nurse assisted in
delivery; complicated cases were brought to a tertiary facil-
ity. Birth weight was measured (within 10 g) immediately af-
ter delivery or, for those born at home, on presentation in the
research clinic.
We collected maternal venous blood, maternal placental
blood,19 cordblood, andplacental biopsieswithin 1hourpost-
partum. For home deliveries, samples were collected within
2 hours postpartum. All women received therapy with arte-
mether-lumefantrine, praziquantel, and albendazole imme-
diately postpartum.
Supplementation with iron or placebo continued for 1
monthpostpartum.We then collectedmaternal venousblood
and neonatal capillary blood. We also extracted information
from antenatal health booklets about IPT use, possession of
mosquitonets, andmicronutrient supplements supplieddur-
ing antenatal visits.
LaboratoryMeasurements
We used dipstick tests (Access Bio) to detect histidine-rich
protein-2 (HRP2) and lactate dehydrogenase (pLDH) specific
to either P falciparum or to nonfalciparum human Plasmo-
dium species. Whereas HRP2-based tests detect current or
recent P falciparum infection, pLDH-based tests only indicate
current infection.20 Placental biopsies were examined
histologically21 to detect Plasmodium infection. We used real-
time polymerase chain reaction (PCR) to detect P falciparum–
specific DNA in erythrocytes and DNA in stool of intestinal
helminths associated with blood loss (Schistosoma spp,
Trichuris trichiura, hookworm).
We assessed plasma iron markers (concentrations of fer-
ritin, soluble transferrin receptor, transferrin) and plasma in-
flammation markers (concentrations of C-reactive protein
[CRP] and α1-acid glycoprotein) on a BeckmanCoulter UniCel
DxC 880i analyzer and HIV infection by point-of-care anti-
body tests.
Outcomes
The primary outcome was defined as past or present mater-
nal Plasmodium infection assessed at parturition, regardless
of species, as indicatedby1ormorepositive results for thepres-
ence of pLDH or HRP2 in plasma or by placental histopathol-
ogy or P falciparum DNA in maternal erythrocytes from ve-
nous or placental blood by PCR test. Secondary (exploratory)
outcomes were patent Plasmodium infection (similarly de-
fined as primary outcome but restricted to ≥1 positive result
from dipstick tests or placental histopathology); presence of
P falciparum DNA (as primary outcome, but restricted to ≥1
positive result for PCR tests); current or recentPlasmodium in-
fection (as primary outcome, but restricted to ≥1 positive re-
sult for dipstick tests or PCR tests); birth weight; gestational
age at delivery; intrauterine growth as indicated by birth-
weight-for-gestational-age z score; and maternal and neona-
tal iron status at 1 month postpartum.
Statistical Analysis
Weused SPSS version 21 (IBM) and a predefined plan (see the
statistical analysis plan in Supplement 2). We estimated ef-
fects when possible; P values, where reported, are 2-sided.
Birth-weight-for-gestational-age z scores were derived with
Kenyan children as a reference22 and a coefficient of varia-
tion of 12.8% (estimated from the present study).
Anemia was defined as a hemoglobin concentration less
than 11g/dL.Aparticipanthadan irondeficiency if ferritin con-
centration was less than 15 μg/L and was “iron-replete” if
ferritin concentration was 15 μg/L or greater without inflam-
mation. Ironstatuswasconsidereduncertain if ferritin concen-
tration was 15 μg/L or greater with inflammation. Inflamma-
tion was defined as concentrations of CRP of greater than
10mg/L or α1-acid glycoprotein greater than 1 g/L.
The preplanned primary analysis was per protocol. It
included all individuals with singleton pregnancies who
complied with intervention (ie, consumed >90% of sched-
uled supplements) and for whom outcomes were available.
We also conducted intention-to-treat analysis with multiple
imputations to replace missing values. Results reported are
by intention-to-treat analysis unless indicated otherwise. In
the analysis of birth weight, infants born at referral facilities
and those born at home whose weight was measured more
than 24 hours postpartum were included in intention-to-
treat analysis but excluded from per-protocol analysis.
For binary outcomes, effects are reported as the absolute
difference inproportionsexcept for the riskof lowbirthweight,
which we also report as a relative effect to facilitate extrapo-
lation of results to different settings. Continuous outcomes
were log-transformedasneeded tonormalizedistributions; ef-
fects and corresponding confidence interval limits were ex-
ponentiatedandexpressedasproportional differences in geo-
metricmeans.Weusedmultiple linear regressionandmultiple
logistic regression to compare effect estimateswith andwith-
out adjustment for baseline factors (gravidity, maternal age,
HIV infection,Plasmodium infection status, hemoglobin con-
centration, iron deficiency, and gestational age). For com-
plete accounting, we report the adjusted effect for the pri-
mary outcome, with the odds ratio re-expressed as a risk
difference; for secondary outcomes (birth weight, gesta-
tionalageatdelivery, andmaternaland infanthemoglobincon-
centration at 30 days after birth), adjusted results are not re-
ported because adjustment did not markedly affect the
magnitude of the intervention effects.
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Weanticipated that ironabsorptionand thus effects of ad-
ministered ironwoulddependonbaseline iron status and that
baseline proxymarkers of immunity against malaria (gravid-
ity, age, HIV infection) might determine the ability to sup-
press apossible increase inparasitemia resulting fromadmin-
istered iron.Weusedstratifiedanddirectmultivariateanalyses
to assess effect modification by these baseline factors, with
Plasmodium infection, birth weight, and maternal hemoglo-
bin concentration at 1month after birth as outcomes.We also
assessed to what extent the use of IPT influenced themagni-
tude of intervention effects.
Results
Of 2015 women invited for screening, 470 (23%) were ran-
domized (237 to the iron group and 233 to the placebo group)
andwere included in the intention-to-treat analysis (Figure 1).
Per-protocol analysis included 430 or fewer cases, depend-
ing on the volume of missing data for each outcome. For the
primary outcome, 363women (77%)were available for analy-
sis with missing data from 55 in the iron group and 52 in the
placebo group. Adherence in the iron andplacebo groupswas
100%and99.1%, respectively.Thegroupswere similar regard-
ing the percentage who received iron supplements supplied
by external sources (9.3% vs 9.9%) andwho possessed insec-
ticide-treated bed nets (15.2% vs 15.9%). Only on 1 occasion
(at baseline) did we find a participant to be infected by a
Plasmodium species other than P falciparum.
We found no evidence that iron supplementation caused
seriousadverseevents (Figure 1 andeTable2 inSupplement3).
Serious adverse eventswere reported for 9 and 12womenwho
received ironandplacebo, respectively. Therewere 2maternal
deaths,whichbothoccurred in theplacebogroup; onewoman
was reported to have died due to postpartumhemorrhage and
another at 2weeks postpartumdue to pneumonia and cardiac
arrest. There were 7 fetal or neonatal deaths in each group; in
addition, 1 child died in each group after 28 days of life.
Four hundred fifteen women (88.3%) delivered new-
borns at the research clinic, 38 (8.1%) in referral hospitals, and
17 (3.6%) at home. Placenta was missing or poorly preserved
for42women (8.9%)due todeliveryathomeor in referral hos-
pitals; in addition, placental biopsies were unavailable for 85
women first enrolled (18.1%) due to incorrect preservation of
samples. Twomothers refusedconsent forneonatal bloodcol-
lection. Plasma sample volumes from 2 infants in the control
group were insufficient for all biochemical tests.
Baseline
Intervention groups were similar except for mild imbalances
in marital status (married or living together: 86.1% vs 79.0%
in groups receiving iron or placebo) and gravidity (secundi-
gravida: 24.1% vs 15.0% in groups receiving iron or placebo)
(Table 1). Of women without inflammation, 59.7% (190/318)
were iron-deficient. Infection by Schistosoma spp and
T trichiurawas relatively common, whereas Necator america-
nus was rarely found. Ancylostoma DNA was absent in all
stool samples.
Table 1. Baseline Characteristics of Study Participants
by Intervention Group
Characteristics Iron Placebo
No. of participants 237 233
Height, mean (SD), cm 162.4 (5.7) 162.4 (6.7)
Weight, mean (SD), kg 58.2 (7.6) 57.5 (7.5)
Body mass index, mean (SD)a 22.1 (2.7) 21.8 (2.6)
Marital status, No. (%)
Married or living together 204 (86.1) 184 (79.0)
Divorced or separated 8 (3.4) 10 (4.3)
Never married 25 (10.5) 39 (16.7)
Age, median (IQR), y 24.0 (20.0-28.5) 24.0 (20.0-29.0)
Gestational age,
median (IQR), wkb
17.6 (15.7-19.6) 17.4 (15.6-19.8)
Gravidity, No. (%)
Primigravida 37 (15.6) 48 (20.6)
Secundigravida 57 (24.1) 35 (15.0)
Multigravida 143 (60.3) 150 (64.4)
Plasmodium infection, No. (%)
Any plasmodium spp by any
dipstick or PCRc
89 (37.6) 86 (36.9)
P falciparum by HRP2- or
pLDH-based dipstick or PCR
88 (37.1) 86 (36.9)
Current or recent P falciparum
infection by either HRP2- or
pLDH-based dipstick
49 (20.6) 46 (19.8)
P falciparum by PCR 81 (34.2) 82 (35.2)
HIV infection, No. (%)d 48 (20.3) 51 (22.1)
Plasma CRP concentration,
median (IQR), mg/L
4.2 (2.1-10.1) 4.3 (2.1-11.0)
Plasma AGP concentration,
mean (SD), g/L
0.8 (0.3) 0.8 (0.3)
Inflammation, No. (%)e
Plasma CRP concentration
≥10 mg/L
61 (25.7) 65 (27.9)
Plasma AGP concentration
≥1.0 g/L
43 (18.1) 42 (18.0)
Plasma CRP concentration
≥10 mg/L or AGP ≥1.0 g/L
76 (32.1) 76 (32.6)
Hemoglobin concentration,
mean (SD), g/dL
11.39 (1.09) 11.25 (1.19)
Anemia, hemoglobin
concentration <11.0 g/dL,
No. (%)
82 (34.6) 93 (39.9)
Plasma ferritin concentration,
median (IQR), μg/L
13.9 (8.2-29.2) 13.8 (8.3-28.5)
Plasma sTfR concentration,
median (IQR), mg/L
1.9 (1.4-2.5) 2.0 (1.6-2.7)
Plasma transferrin
concentration,
mean (SD), g/L
3.1 (0.5) 3.1 (0.6)
Iron deficiency, plasma ferritin
concentration <15 μg/L
All women, No. (%) 126 (53.2) 122 (52.4)
Those with CRP concentration
<10 mg/L, No./total No. (%)
101/176 (57.4) 96/168 (57.1)
Those with AGP concentration
<1.0 g/L, No./total No. (%)
115/194 (59.3) 106/191 (55.5)
Those with concentrations of
CRP <10 mg/L or AGP <1.0 g/L,
No./total No. (%)
97/161 (60.2) 93/157 (59.2)
ZPP-heme ratio, median (IQR),
μmol/mol
Whole blood 89.0 (67.8-119.3) 89.5 (67.3-126.3)
Erythrocyte 37.5 (19.8-63.3) 35.5 (19.8-72.3)
(continued)
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Maternal Outcomes at Delivery
Fortywomen (22 in the irongroupand 18 in theplacebogroup)
were lost to follow-up or excluded at birth. There was no evi-
dent effect of iron supplementation on Plasmodium infection
risk (50.9% vs 52.1% for iron vs placebo groups, respectively;
difference, −1.2%, 95% CI, −11.8% to 9.5%; P = .83) (Table 2).
This effect was not influenced by baseline imbalances (crude
andadjusted riskdifference,−1.2%vs−0.5%). Subgroupanaly-
sis showed no evidence that the effect of iron on Plasmodium
infection risk depended on any of the baseline factors inves-
tigated (Figure 2) or on IPT use (Figure 3).
Iron supplementation led to improvedmaternal iron sta-
tus as indicatedbyhemoglobin concentrations, prevalence of
anemia, and ZPP–heme ratios (Table 2).
Neonatal Outcomes at Delivery
Iron supplementation resulted in increased birth weight by
150 g (95%CI, 56 to 244) (Table 2) and reduced the risk of low
birth weight by 58% (95% CI, 22% to 87%). The absolute risk
reduction was 6.0% (95% CI, 0.8% to 11.1%) (Table 2). Thus,
on average, 16.8 women (95% CI, 9.0 to 61.3) needed to re-
ceive supplementation to prevent 1 case of low birth weight.
The effect of iron on birth weight was larger in women with
irondeficiencyatbaseline than in thosewhowere initially iron-
replete (234 g vs 39 g; difference, 195 g; 95% CI, −3 to 393;
P = .05) (Figure2).Therewasnoevidence that theeffectof iron
on birth weight was influenced by IPT use (Figure 3).
Iron supplementation led to an increased gestational age
at delivery by 3.4 days and neonatal length by 0.9 cm; it re-
duced the risk of premature birth by 7% (Table 2). We found
no effect of iron on neonate iron markers (hemoglobin con-
centration, ZPP-heme ratios).
Maternal Outcomes at 1 Month After Birth
Twelve mothers were lost to follow-up postpartum (5 in the
iron group and 7 in the placebo group). Iron supplementation
improvedmaternal ironstatus.Hemoglobinconcentrationand
geometric mean plasma ferritin concentration increased by
0.90 g/dL and 123%, respectively; geometric mean plasma
transferrin receptor concentration was reduced by 29%
(Table 3). Gains in iron statusweregreater inwomenwithpoor
iron status at baseline. Iron supplementation increased he-
moglobin concentration by 1.52 g/dL and0.44 g/dL inwomen
with andwithout initial anemia, respectively. Corresponding
valueswere 1.29 g/dL and0.60g/dL forwomenwhowere ini-
tially iron-deficient and -replete, respectively (Figure 2).
Neonatal Outcomes at 1 Month Postpartum
Twenty-two infantswere lost to follow-up (13 in the irongroup
and 9 in the placebo group). Iron supplementation increased
geometric mean plasma ferritin concentration by 18%. There
wasnoevidence that it affectedhemoglobinandplasma trans-
ferrin receptor concentrations.
Per-Protocol Analysis
Results of the per-protocol analysis were similar to those ob-
tained by intention-to-treat analysis (eTables 3 and 4, eFig-
ures 1 and 2 in Supplement 3). There was no evident effect of
irononPlasmodium infection,howeverdefined (eTables4and
5 in Supplement 3). Iron supplementation led to a decrease in
the riskof lowbirthweightby64%(95%CI, 12%-86%).Among
women who were initially iron deficient, iron supplementa-
tion increased birth weight by 263 g (95% CI, 136-362). There
was someevidence that IPTusemodified the effect of iron on
maternal hemoglobin concentration (P = .04 for interaction),
but there was no monotonic trend in effect by IPT dose.
Discussion
Overall,we foundnoeffect of daily iron supplementationdur-
ing pregnancy on risk ofmaternalPlasmodium infection. Iron
supplementation resulted in an increased birth weight (by
150g),gestationalduration,andneonatal length;enhancedma-
ternal and infant iron stores at 1 month after birth; and a de-
creased riskof lowbirthweight (by58%)andprematurity. The
Table 1. Baseline Characteristics of Study Participants
by Intervention Group (continued)
Characteristics Iron Placebo
Intestinal helminth infectionsf
Schistosoma spp, No. (%)
Absent (Ct = 45) 165 (69.7) 149 (63.7)
Low (35 < Ct < 45) 10 (4.4) 10 (4.2)
Moderate (30 ≤ Ct ≤ 35) 22 (9.4) 19 (8.0)
High (Ct < 30) 39 (16.6) 56 (24.1)
Trichuris trichiura, No. (%)
Absent (Ct = 45) 185 (78.1) 198 (84.8)
Low (35 < Ct < 45) 8 (1.0) 8 (3.4)
Moderate (30 ≤ Ct ≤ 35) 12 (4.9) 13 (5.5)
High (Ct < 30) 32 (13.5) 15 (6.2)
Necator americanus, No. (%)
Absent (Ct = 45) 211 (88.9) 209 (89.8)
Low (35 < Ct < 45) 9 (3.7) 9 (3.9)
Moderate (30 ≤ Ct ≤ 35) 10 (4.2) 10 (4.2)
High (Ct < 30) 8 (3.2) 5 (2.0)
Abbreviations: AGP, α1-acid glycoprotein; CRP, C-reactive protein;
Ct, cycle threshhold; HRP2, P falciparum–specific histidine-rich protein-2;
IQR, interquartile range; pLDH, P falciparum-specific lactate dehydrogenase;
PCR, polymerase chain reaction; sTfR, soluble transferrin receptor; ZPP, zinc
protoporphyrin.
a Calculated as weight in kilograms divided by height in meters squared.
bAll women except 1 were in the second trimester of pregnancy.
c Only 1 participant (iron group) had infection by a Plasmodium species other
than P falciparum.
dHIV status of 2 participants was not determined.
e Only 1 participant (iron group) had current fever defined as axillary
temperature37.5°C.
f Missing values occurred because stool samples could not be collected for
somewomen. Cycle threshold values are inversely proportional to the amount
of target DNA in the sample. Ct = 45: no detectable levels of target nucleic
acid; 35 < Ct < 45: weak reactions indicative of marginal amounts of target
nucleic acid; 30  Ct  35: positive reactions indicative of moderate amounts
of target nucleic acid, compatible with low parasite load that is unlikely to be
detectable bymicroscopy; Ct < 30: strong positive reactions indicative of
abundant target nucleic acid compatible with a parasite load that is probably
detectable bymicroscopy.
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effect on birth weight was influenced by initial maternal iron
status. Correction of maternal iron deficiency led to an in-
crease in birth weight by 239 g.
Supplementation with iron-containing micronutrients
can increase malaria rates in young children with iron
deficiency,23 perhaps through transiently increased counts
of young erythrocytes that are more susceptible to invasion
and propagation by P falciparum merozoites than mature
erythrocytes.24 Although we found no evidence in the
present study that iron increased Plasmodium infection risk
in women who were iron-deficient or anemic at baseline, we
could not exclude such an effect (see upper limit of 95% CIs
Table 2. Effect of Iron on SelectedMaternal and Neonatal Outcomes at Deliverya
Indicator
No. of Missing Outcome Data
(% of Randomized Persons)
Iron
(n = 237)
Placebo
(n = 233) Effect (95% CI) P ValueIron Placebo
Maternal outcomes
Plasmodium infection, %
Any evidence of infection (primary outcome)b 55 (23.2) 52 (22.3) 50.9 52.1 −1.2
(−11.8 to 9.5)
.83
Patent infectionc 57 (24.1) 59 (25.3) 47.3 45.6 1.7
(−8.5 to 11.9)
.74
Presence of P falciparum DNAd 22 (9.3) 21 (9.0) 25.1 26.9 −1.8
(−11.1 to 7.4)
.69
Current or recent infectione 56 (23.6) 52 (22.3) 38.6 40.0 −1.4
(−12.8 to 10.0)
.81
Hemoglobin concentration, g/dL 22 (9.3) 19 (8.2) 12.08 11.15 0.93
(0.59 to 1.26)
<.001
Anemia (hemoglobin concentration
<11.0 g/dL), %
22 (9.3) 19 (8.2) 22.0 50.4 −28.4
(−36.9 to −19.8)
<.001
Hemoglobin concentration >13.0 g/dL, % 22 (9.3) 19 (8.2) 31.3 17.3 14.0
(6.0 to 22.0)
<.001
ZPP-heme ratio, μmol/mol
Whole blood 21 (8.9) 16 (6.9) 108.7 158.3 −31.3%
(−37.9% to −24.0%)f
<.001
Erythrocyte 23 (9.7) 16 (6.9) 29.9 66.9 –55.3%
(–62.5% to –46.7%)f
<.001
Neonatal outcomes
Birth weight, gg 28 (11.8) 23 (9.9) 3202 3053 150
(56 to 244)
.002
Low birth weight (<2500 g), % 28 (11.8) 23 (9.9) 4.3 10.3 −6.0
(−11.1 to −0.8)
.02
Gestational age at delivery, d 1 (0.4) 1 (0.4) 274.4 271.0 3.4
(0.8 to 5.9)
.009
Premature birth (<37 wk gestation), % 1 (0.4) 1 (0.4) 9.1 16.2 −7.1
(−13.2 to −1.1)
.02
Birth-weight-for-gestational-age z score 27 (11.4) 25 (10.7) 0.52 0.31 0.21
(−0.11 to 0.52)
.20
Length, cm 40 (16.9) 36 (15.5) 50.6 49.7 0.9
(−0.1 to 1.8)
.07
Head circumference, cm 40 (16.9) 35 (15.0) 34.9 34.6 0.3
(−0.2 to 0.8)
.28
Hemoglobin concentration in cord blood, g/dL 31 (13.1) 24 (10.3) 15.43 15.11 0.32
(−0.11 to 0.75)
.14
ZPP-heme ratio, μmol/mol
Cord blood 31 (13.1) 25 (10.7) 138.6 139.7 −0.8%
(−7.8% to 6.6%)f
.82
Cord erythrocyte 31 (13.1) 25 (10.7) 55.3 55.8 −0.9%
(−11.9% to 11.5%)f
.88
Abbreviations: HRP2, P falciparum–specific histidine-rich protein-2; pLDH,
P falciparum-specific lactate dehydrogenase; PCR, polymerase chain reaction;
ZPP, zinc protoporphyrin.
a Values indicate group prevalence or groupmean, and effects are indicated as
absolute difference unless indicated otherwise. SeeMethods for definitions of
indicators.
bAt least 1 positive result for dipstick tests (HRP2 or pLDH for any human
Plasmodium species) in maternal venous or placental blood, or by
P falciparum–specific PCR tests in maternal erythrocytes from venous or
placental blood, or presence of parasites or pigment in placental biopsies by
histopathology.
c At least 1 positive result for dipstick tests (HRP2 or pLDH for any human
Plasmodium species) in maternal venous or placental blood or presence of
parasites or pigment in placental biopsies by histopathology.
d Presence of P falciparum–specific DNA inmaternal erythrocytes from venous
or placental blood by PCR test.
e At least 1 positive result for dipstick tests (HRP2 or pLDH for any human
Plasmodium species) in maternal venous or placental blood, or presence of
parasites in maternal erythrocytes or pigment in erythrocytes/monocytes in
intervillous space by placental histopathology.
f Relative differences in geometric means, with placebo as the reference group.
g Including neonates born in hospital or for whomweight was measured after
24 hours postpartum.
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Figure 2. Effect of Iron Supplementation on Selected Outcomes by Subgroup
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in Figure 2). Should this raise concerns? P falciparum infec-
tions in pregnancy notably cause increased risks of low birth
weight and severe anemia.12 In our study, however, women
who were initially iron-deficient benefited most in terms of
birth weight, indicating that any potential decrease in birth
weight due to the effect of iron supplements on Plasmodium
infection was outweighed by beneficial effects of iron on
birth weight through other mechanisms.
Depending on local conditions, approximately one-
quarter of severe anemia cases amongpregnantwomenare at-
tributable to malaria,12 suggesting that most cases are due to
iron deficiency. Our data show that women who were ini-
tially iron-deficient or anemic benefited particularly in terms
ofhemoglobinconcentrations (Figure2), thusdecreasing their
riskof severeanemia.Womenwith increasedhemoglobincon-
centrationsdue to ironsupplementationmayalsobe lessprone
todevelop severe anemiaduring or following episodes ofma-
larial illness.
Per-protocol analysis suggested that IPT use may have
modified the effect of iron on hemoglobin concentration
(eFigure 2 in Supplement 3), but the absence of a clear trend
with dose indicates that this finding may be spurious. Inter-
pretation of these data is further complicated because IPT
use was not a baseline factor andmay have acted as amediat-
ing factor.
One limitationofourstudyconcerns themissingdata.Mul-
tiple imputation yields valid effect estimates when data are
missing at random,25 which seems a reasonable assumption
given the reasons for missingness of most primary outcome
data (exclusionof twinpregnancies,women leaving the study
area, absent placental samples because of delivery at homeor
in tertiary facilities, or incorrect preservation of samples).
Another limitation of our study concerns the lack of de-
tailed, reliablemorbiditydataduring follow-up.Toavoid ethi-
cal dilemmas, we did not collect blood samples during inter-
vention, and we referred women for antenatal care after
enrollment toregularhealthservices,where theyreceivedstan-
dardservice.Plasmodium infectionwasdetermined insamples
collected at delivery, which may not have captured all infec-
tions or symptomatic episodes during intervention. Plasmo-
dium pigment persists in the placenta, however, and placen-
tal histopathology probably captures most infections in the
second half of pregnancy, even though it may have low sen-
sitivity in capturing earlier infections.21,26
Figure 3. Effect of Iron Supplementation on Selected Outcomes by Use of Intermittent Preventive Treatment
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The use of placebo in a population that included women
with anemia and iron deficiency was justified by our concern
that risks inherent to iron supplementation outweighed pos-
sible benefits; however, it also provided a unique opportu-
nity to assess benefits of antenatal iron supplementation.
Recent meta-analyses, published after we started our trial,
found no27 or only small effects (31 g28 and 41 g29) of antena-
tal iron supplementation on birth weight. In these meta-
analyses, however, subgroup analysis by initial iron status
could not be investigated, because women with anemia or
iron deficiency were excluded from the studies reviewed,
women (also in the placebo group) received iron as rescue
therapy during intervention, or initial anemia status and iron
status had not been specified.27 Consistent with the findings
reported in thesemeta-analyses,27-29 our data showed no evi-
dent effect of iron on birth weight among iron-replete
women.
Thebeneficial effect ofmaternal iron supplementationon
birthweight found in our studymay also be explained in part
by a superior adherence comparedwithprevious studies.27-29
Whereasweobserveddailywhetherwomenswallowedsupple-
mental capsules, supervisionwas unclear in other studies, or
contactwithparticipantswas limited to repeatedvisits or tele-
phone calls. Although several studies used capsules or coated
tablets,30,31 ironwasmostly givenas tabletswith ferrous salts,
which produce a strong, unpleasant taste that may have dis-
couraged adherence. Attrition was high in many studies, al-
though it is unclear whether this occurred selectively in the
iron groups. Adherence in most studies was not reported or
poor, or supplementusewas assessedby tablet counts or self-
reports, which tend to overestimate adherence.32,33
The gain in birth weight was due at least in part to a lon-
ger gestational duration, with perhaps some contribution by
improved fetal growth. Inmagnitude, this effect (150g) is com-
parable or exceeds effects of interventions to preventmalaria
in pregnancy, namely, IPT (79-135 g, depending on frequency
of administration) and insecticide-treatednets (55 g),34 and is
particularly important because low birthweight is associated
with neonatal and postneonatal mortality, morbidity, inhib-
ited growth, cognitive development, and potentially chronic
diseases later in life.35This comparisonshouldnotdetract from
thebenefitsof thesemalaria control interventions,but is rather
made to indicate the importance that should be given to in-
creased coverage of iron supplementation.
In accordance with our finding on birth weight, the he-
moglobin response to ironwas larger inwomenwhowere ini-
tially iron-deficient as compared with those who were iron-
replete. A differential benefit of iron by anemia status was
Table 3. Effect of Iron on SelectedMaternal and Neonatal Outcomes at 1 Month After Birtha
Indicator
No. of Missing Outcome Data
(% of Randomized Persons)
Iron
(n = 237)
Placebo
(n = 233) Effect (95% CI) P ValueIron Placebo
Maternal outcomes
Hemoglobin concentration, g/dL 22 (9.3) 19 (8.2) 12.89 11.99 0.90
(0.61 to 1.19)
<.001
Anemia (hemoglobin concentration
<12.0 g/dL), %
22 (9.3) 19 (8.2) 43.2 65.7 −22.4
(−31.4 to −13.5)
<.001
Plasma ferritin concentration, μg/L 23 (9.7) 21 (9.0) 32.1 14.4 123.4%
(85.5% to 169.1%)b
<.001
Iron deficiency (plasma ferritin concentration
<15 μg/L)
All persons, % 23 (9.7) 21 (9.0) 19.8 56.0 −36.2
(−44.9 to −27.5)
<.001
Those without inflammation, %c 23 (9.7) 21 (9.0) 21.1 59.5 −38.5
(−49.7 to −27.3)
<.001
Plasma transferrin concentration, g/L 24 (10.1) 21 (9.0) 2.67 3.07 −0.40
(−0.49 to −0.30)
<.001
Plasma transferrin receptor concentration, mg/L 23 (9.7) 21 (9.0) 1.81 2.53 −28.6%
(−35.5% to −21.0%)b
<.001
ZPP-heme ratio, μmol/mol
Whole blood 22 (9.3) 19 (8.2) 100.4 152.0 −33.9%
(−40.3% to −26.8%)b
<.001
Erythrocyte 24 (10.1) 19 (8.2) 31.9 74.5 −52.7%
(−64.0% to −49.1%)b
<.001
Neonatal outcomes
Hemoglobin concentration, g/dL 33 (13.9) 30 (12.9) 13.45 13.32 0.13
(−0.52 to 0.78)
.69
Plasma ferritin concentration, μg/L 34 (14.3) 31 (13.3) 163.0 138.7 17.5%
(2.4% to 34.8%)b
.02
Plasma transferrin receptor concentration, mg/L 35 (14.8) 31 (13.3) 1.21 1.27 −4.4%
(−11.3% to 2.9%)b
.23
Abbreviation: ZPP, zinc protoporphyrin.
a Values indicate group prevalence or groupmean, and effects are absolute
differences unless indicated otherwise. SeeMethods for definitions of
indicators.
b Relative differences in geometric means, with placebo as the reference group.
c Concentrations of C-reactive protein <10mg/L and α1-acid glycoprotein
<1.0 g/L.
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apparent for hemoglobin concentration but not birth weight
(Figure2), consistentwith initial anemiabeingdueonlypartly
to iron deficiency and partly to other causes.
Our finding of increasedplasma ferritin concentrations at
1 month postpartum adds to growing evidence,36 so far con-
firmed only in a single trial,37 that antenatal iron supplemen-
tation improves neonatal iron stores, thus delaying the age at
which iron deficiency is likely to develop during infancy.
Thebaseline characteristics of our studypopulationwere
typical for pregnantwomen inmany rural settings in low- and
middle-income countries. There was no evidence that gains
in birth weight depended on gravidity, maternal age, HIV in-
fection, anemia, and IPTuse, suggestingbenefits from iron for
all subgroups thusdefined, includingprimigravidaeand those
who did not receive IPT. Thus, our results may apply to preg-
nant women in other low- and middle-income countries, al-
though the effect on birth weight can vary depending on the
prevalence of iron deficiency. Our results cannot be extrapo-
lated to daily antenatal supplementation with 120 mg, for
which safety data are lacking, or to children, for whom there
is substantial evidence that iron supplementation can in-
crease malaria rates.38
In low- and middle-income countries, it is generally im-
practical to screen for ironstatus, andmostcountrieshavepoli-
cies for universal iron supplementation for pregnantwomen.
Based on our results, we believe that the benefits of universal
supplementation outweigh possible risks.
Conclusions
Among rural Kenyanwomenwith singleton pregnancies, ad-
ministrationofdaily ironsupplementation, comparedwithad-
ministration of placebo, resulted in no significant differences
in overall maternal Plasmodium infection risk. Iron supple-
mentation led to increased birth weight.
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